TriNetX Survey: Biopharma Embraces AI & RWD, Faces Barriers
Real-world data (RWD), artificial intelligence (AI), and patient-centric trial design lead pharma priorities in 2025, but data compatibility, regulatory hurdles, and security concerns threaten to stall momentum. As biopharmaceutical companies double down on innovation and patient-centric research, a new industry survey from studioID and TriNetX reveals widespread integration of RWD and AI in drug development…
